Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current valuation is attractive for a potential shot on goal in rheumatoid arthritis – RA – a field with limited innovation in many years despite modest efficacy with most agents, the analyst tells investors in a research note. Wolfe adds that currently, the stock is likely trading below its deserved valuation due to a negative halo lingering after the December 2024 termination of the BTLA asset in phase 2 atopic dermatitis, but the firm is bullish into two near-term readouts with rosnilimab Week 12 RA topline expected in February and Week 28 RA topline expected in Q2.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio initiated with an Outperform at Wolfe Research
- AnaptysBio Partners with Vanda for Imsidolimab Development
- AnaptysBio, Vanda announce exclusive global license agreement for Vanda
- Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
- AnaptysBio price target lowered to $36 from $66 at JPMorgan